Alamar Biosciences (ALMR) Q2 FY26 earnings call

Alamar Biosciences reported a strong second quarter, driven by exceptional consumable revenue growth and expanding platform adoption in neurodegenerative and inflammation research. The company is strategically investing in commercial expansion, manufacturing capacity, and R&D to support future growth, while also laying the groundwork for clinical diagnostics with planned FDA marketing authorization for ARGO HT/DX and new partnerships.